Korean drug makers shy of M&A

Published: 2012-07-16 06:59:00

Updated: 2012-07-16 06:59:00

Companies could benefit from mergers and acquisitions (M&As) in the changing business environment of the 21st century, but Korean drug firms are still showing a negative attitude towards M&As due to little synergistic effects and similar production structure among makers.

So far, Korean compan...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK